Skip to main content
. 2017 Jun 14;8(32):52142–52155. doi: 10.18632/oncotarget.18479

Table 4. Comparison between changes of ESR1 and PIK3CA mutations and each therapeutic drug in 52 MBC patients with longitudinal data.

Genomic state No. of patients (%)
Representative treatment between blood draws
Total No AI SERM SERD EE2 MPA Chemotherapy
(N = 52) (N = 7) (N = 15) (N = 5) (N = 8) (N = 5) (N = 2) (N = 10)
ESR1 WT 28 (53.8) 7 (100) 9 (60) 1 (20) 1 (12.5) 2 (40) 1 (50) 7 (70)
Acquires or maintenance of mutation numbers 15 (28.8) 0 4 (26.7) 2 (40) 5 (62.5) 1 (20) 1 (50) 2 (20)
Disappears in mutation numbers 9 (17.3) 0 2 (13.3) 2 (40) 2 (25) 2 (40) 0 1 (10)
PIK3CA WT 31 (59.6) 7 (100) 10 (75) 3 (60) 5 (62.5) 2 (40) 1 (50) 3 (30)
Acquires or maintenance of mutation numbers 18 (34.6) 0 5 (25) 1 (20) 3 (37.5) 3 (60) 1 (50) 5 (50)
Disappears in mutation numbers 3 (5.8) 0 0 1 (20) 0 0 0 2 (20)

Abbreviations: WT, wild-type; AI, aromatase inhibitor; SERM, selective estrogen receptor modulator; SERD, selective estrogen receptor downregulator; EE2, Ethinyl estradiol; MPA, medroxyprogesterone acetate.